Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | USP5 | P45974 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577288 | 0.93 | CHRM3 (0.56) | ACKR3CHRM3DRD4DRD2CHRM4 | |
| SCHEMBL5577295 | 0.90 | SMN1; SMN2 (0.53) | CHRM3ALDH1A1GAAMCHR1POLB | |
| SCHEMBL5577786 | 0.89 | MEN1 (0.50) | ACKR3CHRM3DRD2CHRM4ALDH1A1 | |
| SCHEMBL5577414 | 0.89 | CHRM3 (0.48) | ACKR3CHRM3DRD2CHRM4ALDH1A1 | |
| SCHEMBL5577402 | 0.89 | MEN1 (0.56) | DRD4DRD2CHRM4ALDH1A1KMT2A | |
| SCHEMBL5577658 | 0.89 | CHRM3 (0.47) | ACKR3CHRM3DRD2CHRM4ALDH1A1 | |
| SCHEMBL5577332 | 0.88 | KMT2A (0.48) | CHRM3DRD4DRD2ALDH1A1GAA | |
| SCHEMBL5577685 | 0.88 | KMT2A (0.46) | ACKR3CHRM3DRD4DRD2ALDH1A1 | |
| SCHEMBL5577672 | 0.88 | KMT2A (0.51) | ACKR3CHRM3CXCR3POLBKMT2A | |
| SCHEMBL5577810 | 0.86 | ALDH1A1 (0.56) | DRD4DRD2ALDH1A1GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | ACKR3 389/4885CHRM3 2099/4885DRD4 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.